179 related articles for article (PubMed ID: 24817435)
1. Compliance after switching from branded to generic statins.
Romanelli RJ; Jukes T; Segal JB
Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1093-100. PubMed ID: 24817435
[TBL] [Abstract][Full Text] [Related]
2. Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.
Romanelli RJ; Segal JB
J Gen Intern Med; 2014 Oct; 29(10):1372-8. PubMed ID: 24957381
[TBL] [Abstract][Full Text] [Related]
3. Generic and therapeutic statin switches and disruptions in therapy.
Chapman RH; Benner JS; Girase P; Benigno M; Axelsen K; Liu LZ; Nichol MB
Curr Med Res Opin; 2009 May; 25(5):1247-60. PubMed ID: 19344292
[TBL] [Abstract][Full Text] [Related]
4. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
5. Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry.
O'Brien EC; McCoy LA; Thomas L; Peterson ED; Wang TY
Am Heart J; 2015 Jul; 170(1):55-61. PubMed ID: 26093864
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.
Gagne JJ; Choudhry NK; Kesselheim AS; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Ann Intern Med; 2014 Sep; 161(6):400-7. PubMed ID: 25222387
[TBL] [Abstract][Full Text] [Related]
7. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
Sedjo RL; Cox ER
Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
[TBL] [Abstract][Full Text] [Related]
8. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
9. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.
Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J
Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491
[TBL] [Abstract][Full Text] [Related]
10. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
11. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
[TBL] [Abstract][Full Text] [Related]
12. Patient co-payment and adherence to statins: a review and case studies.
Simoens S; Sinnaeve PR
Cardiovasc Drugs Ther; 2014 Feb; 28(1):99-109. PubMed ID: 24150747
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
Hess G; Sanders KN; Hill J; Liu LZ
Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116
[TBL] [Abstract][Full Text] [Related]
14. The need for a systematic approach to statin switching: an analysis of real-world experience.
Kakavas PW; McManus JL; Wolfe TA; Guidry T; Flores DN; Ter Riet LB; Glover JJ; Sell H
J Cardiovasc Nurs; 2013; 28(6):565-72. PubMed ID: 23064180
[TBL] [Abstract][Full Text] [Related]
15. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
[TBL] [Abstract][Full Text] [Related]
16. Capsule commentary on Romanelli et al., predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.
Pathak H
J Gen Intern Med; 2014 Oct; 29(10):1391. PubMed ID: 25103124
[No Abstract] [Full Text] [Related]
17. The effect of switching on compliance and persistence: the case of statin treatment.
Thiebaud P; Patel BV; Nichol MB; Berenbeim DM
Am J Manag Care; 2005 Nov; 11(11):670-4. PubMed ID: 16268750
[TBL] [Abstract][Full Text] [Related]
18. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans.
Marelli C; Gunnarsson C; Ross S; Haas S; Stroup DF; Cload P; Clopton P; DeMaria AN
J Am Coll Cardiol; 2011 Jul; 58(5):530-7. PubMed ID: 21777752
[TBL] [Abstract][Full Text] [Related]
19. Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data.
Talic S; Marquina C; Ofori-Asenso R; Petrova M; Liew D; Owen AJ; Lybrand S; Thomson D; Ilomaki J; Zomer E; Ademi Z
Cardiovasc Drugs Ther; 2022 Oct; 36(5):867-877. PubMed ID: 34097194
[TBL] [Abstract][Full Text] [Related]
20. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study.
Ye X; Gross CR; Schommer J; Cline R; St Peter WL
Clin Ther; 2007 Dec; 29(12):2748-57. PubMed ID: 18201593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
